China Biotech Services Holdings Ltd, formerly Rui Kang Pharmaceutical Group Investments Ltd, is an investment holding company principally engaged in the provision of medical health check services. The Company operates its business through six segments. The Medical and Health Related Services segment provides medical laboratory testing services and health check services. The Insurance Brokerage segment is engaged in the provision of brokerage services. The Immunotherapy segment provides tumor immune call therapy, immune cell storage and health management services. The Pharmaceutical Products segment is engaged in the manufacture, research and development, sale and distribution of health related and pharmaceutical products. The Securities segment is engaged in the trading of securities. The Others segment is engaged in the money lending business and provision of logistic services.

Employees

142

Sector

Healthcare Facilities & Services

More about the company

Quotes

Date	Price	Change	Volume
24/07/26	HK$0.6400	-1.54%	505,000
23/07/26	HK$0.6500	0.00%	180,000
22/07/26	HK$0.6500	-1.52%	220,000
21/07/26	HK$0.6600	+1.54%	575,000
20/07/26	HK$0.6500	0.00%	175,000

Delayed Quote Hong Kong S.E.

More quotes

Income Statement and Estimates

More financial data

Market Closed - Hong Kong S.E. Other stock markets 09:08:05 24/07/2026 BST			5-day change	1st Jan Change
0.6400 ^HKD	-1.54%		-9.86%	-18.99%

05-18	China Biotech Services' unit disposes entire stake in PHC Medical Diagnostic Centre, others	RE
04-30	China Biotech Services says He Xun resigns as executive director	RE

Market Cap	624M 79.63M 69.94M 65.04M 59.68M 112M 7.67B 114M 772M 302M 3.77B 299M 292M 13.03B	P/E 2024	-2.49x	P/E 2025	-11.2x
Enterprise Value	1.01B 128M 113M 105M 96.27M 181M 12.37B 184M 1.25B 487M 6.08B 482M 472M 21.03B	EV / Sales 2024	9.45x	EV / Sales 2025	15.7x
Free-Float	35.46%	Yield 2024 *	-	Yield 2025	-

05-18	China Biotech Services' unit disposes entire stake in PHC Medical Diagnostic Centre, others	RE
04-30	China Biotech Services says He Xun resigns as executive director	RE
04-30	China Biotech Services Holdings Limited Announces Resignation He Xun as Executive Director, Effective May 1, 2026	CI
04-28	China Biotech Services Holdings Limited Auditor Raises 'Going Concern' Doubt	CI
03-27	China Biotech Services Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-06	China Biotech Services expects FY net loss of not more than HK$100 million	RE
03-06	China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2025	CI
02-19	China Biotech Services Holdings Limited announced that it has received HKD 272.3 million in funding from Wealth Strategy Holding Ltd	CI
12-30	China Biotech Services to issue convertible bonds	RE
12-28	China Biotech Services Holdings Limited announced that it expects to receive HKD 272.3 million in funding	CI
29/09/25	China Biotech Services says outstanding convertible bonds amount to $6 million	RE
11/09/25	China Biotech Services' unit enters loan contract with Hainan Rural Commercial Bank	RE
27/08/25	China Biotech Services Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI

10/01/23	China Biotech Services subsidiary AMDL nominated as Top Clinical Laboratory Services Company in APAC 2022 and receives CAP Accreditation Certificate	AQ
24/06/22	Sumitomo Heavy Industries, Ltd. - Notice Regarding Our First Overseas Introduction of BNCT in the Hainan Medical Tourism Pilot Zone, China	AQ
10/08/21	China Biotech Services : AMDL, a Subsidiary of China Biotech Services, is Exclusively Licensed to Distribute FDA Approved Lung & Colon Cancer Companion Diagnostic Assay in Several Asian Regions Including China	AQ
28/06/21	China Biotech Services (8037.HK): Confident shareholders are taking long on their books in anticipation of promising results to be generated from the double engines of growth on cell therapy and precision diagnostic businesses	AQ
29/01/21	China Biotech Services : Shanghai Longyao Chief Scientist Professor Xuanming Yang published a research article on optimizing CAR-T cells function with independently expressed full-length OX40	AQ

China Biotech Services Holdings Limited Share Price

Stocks

8037

BMG2152F1014

Healthcare Facilities & Services

Valuation: China Biotech Services Holdings Limited

Chart: China Biotech Services Holdings Limited

Latest news : China Biotech Services Holdings Limited

Press Releases: China Biotech Services Holdings Limited

Quotes and Performance

Course Extremes

Managers and Directors: China Biotech Services Holdings Limited

Latest insider transactions

Other Healthcare Facilities & Services

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	-1.54%
1 week	-9.86%
Current month	+47.13%
1 month	+18.52%
3 months	-7.25%
6 months	-15.79%
Current year	-18.99%

1 week	0.58	0.7
1 month	0.42	0.73
Current year	0.3	0.92
1 year	0.3	1.33
3 years	0.25	1.33
5 years	0.25	2.64
10 years	0.16	2.64

Manager	Title	Age	Since
Eddy Lai DFI	Director of Finance/CFO	-	-
Xiao Lin Liu CMP	Compliance Officer	55	25/05/2022
Xuan ming Yang CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Guo Xiang Yan BRD	Director/Board Member	60	06/08/2017
Song Huang BRD	Director/Board Member	44	14/09/2017
Xiao Lin Liu CHM	Chairman	55	27/08/2017

Date	Insider	Type	Main position	Quantity	% Market Cap.
30/03/26	Xiao Lin Liu	Other	Chairman	3,600,000	0.3690%
02/09/24	Xun He	Other	Director	3,220,000	0.3300%
13/06/24	Hoi Yam Chui	Other	Director	5,000,000	0.5191%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CHINA BIOTECH SERVICES HOLDINGS LIMITED	-1.54%	-9.86%	-16.88%	-13.51%	80.89M
CVS HEALTH CORPORATION	+0.80%	+0.25%	+83.39%	+41.86%	136B
HCA HEALTHCARE, INC.	+1.51%	+2.97%	+11.92%	+34.02%	83.52B
FRESENIUS SE & CO. KGAA	+2.22%	+4.71%	+4.56%	+53.85%	27.44B
QUEST DIAGNOSTICS INCORPORATED	-0.02%	+8.15%	+32.55%	+58.21%	25.23B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+1.32%	0.00%	-14.98%	-28.49%	20.05B
TENET HEALTHCARE CORPORATION	+17.17%	+19.64%	+57.16%	+203.29%	17.14B
REDE D'OR SÃO LUIZ S.A.	-0.86%	-6.71%	+2.39%	-7.05%	14.55B
DAVITA INC.	+0.50%	-0.65%	+62.63%	+130.60%	15.04B
FRESENIUS MEDICAL CARE AG	+0.65%	+2.90%	-5.83%	-11.44%	12.98B
Average	+2.22%	-0.31%	+21.69%	+46.13%	35.24B
Weighted average by Cap.	+1.79%	+0.22%	+42.26%	+45.75%

	2024	2025
Net sales	70.51M 8.99M 7.9M 7.34M 6.74M 12.66M 866M 12.86M 87.21M 34.07M 426M 33.75M 33.02M 1.47B	73.5M 9.37M 8.23M 7.66M 7.03M 13.2M 903M 13.4M 90.91M 35.52M 444M 35.19M 34.43M 1.53B
Net income	-198M -25.27M -22.19M -20.64M -18.94M -35.58M -2.43B -36.13M -245M -95.75M -1.2B -94.85M -92.81M -4.14B	-68.78M -8.77M -7.7M -7.16M -6.57M -12.35M -845M -12.54M -85.06M -33.23M -415M -32.92M -32.21M -1.44B
Net Debt	169M 21.54M 18.92M 17.59M 16.14M 30.33M 2.07B 30.8M 209M 81.62M 1.02B 80.86M 79.12M 3.53B	383M 48.81M 42.87M 39.87M 36.59M 68.75M 4.7B 69.81M 473M 185M 2.31B 183M 179M 7.99B